• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    3/16/26 12:32:05 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLTO alert in real time by email
    false --12-31 0001907223 0001907223 2026-03-11 2026-03-11 0001907223 dei:FormerAddressMember 2026-03-11 2026-03-11 0001907223 us-gaap:CommonStockMember 2026-03-11 2026-03-11 0001907223 KLTO:WarrantsMember 2026-03-11 2026-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 11, 2026

     

    Greenland Mines Ltd

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-41340   86-2727441
    (Commission File Number)   (IRS Employer
    Identification No.)

     

    1300 South Boulevard, Suite D

    Charlotte, NC 28203

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code (833) 931-6330

     

    Klotho Neurosciences, Inc.

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Common Stock   KLTO   The Nasdaq Stock Market LLC
    Warrants   KLTOW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03 – Amendments to Articles of Incorporation

     

    On March 11, 2026, the registrant, then known as Klotho Neurosciences, Inc. (the “Company”) filed a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware to merge the Company’s newly formed GML Subsidiary Corp. into the Company, with the Company being the surviving entity and effectuating, pursuant to Section 253(b) of the Delaware General Corporation Law, a change in the Company’s name from Klotho Neurosciences, Inc. to Greenland Mines Ltd. The name change became effective at 5:00 PM on March 11, 2026.

     

    A copy of the Certificate of Ownership and Merger is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 7.01 – Regulation FD Disclosure.

     

    On March 12, 2026, the Company issued a press release regarding its name and trading system change. A copy of the press release is attached hereto as Exhibit 99.1.

     

    The information contained in this Item 7.01 and Exhibit 99.1, attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended or the Securities Act of 1933, as amended whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

     

    This Form 8-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

     

    Item 8.01 – Other Events

     

    In connection with the Company’s name change, the stock symbol for the Company’s common stock was changed and the Company’s common stock began trading under the symbol “GRML” on the Nasdaq Capital Market at the start of trading on March 12, 2026. The CUSIP number for the Company’s common stock remains unchanged.

     

    Item 9.01 – Financial Statements and Exhibits.

     

    Exhibits   Description
    3.1   Certificate of Ownership and Merger
    99.1   March 12, 2026 Press Release
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 16, 2026 Greenland Mines Ltd
         
      By: /s/ Joseph Sinkule
      Name:  Joseph Sinkule
      Title: Chief Executive Officer

     

    2

     

    Get the next $KLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 4:12:10 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 4:02:24 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 3:58:02 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

    3/12/26 10:27:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

    3/9/26 8:30:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

    Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

    3/4/26 8:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    SEC Filings

    View All

    Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Greenland Mines Ltd (0001907223) (Filer)

    3/16/26 12:32:05 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Greenland Mines Ltd (0001907223) (Filer)

    3/12/26 4:00:51 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

    3/10/26 5:00:26 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

    3/12/26 10:27:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

    3/9/26 8:30:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board

    NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

    12/9/24 11:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Financials

    Live finance-specific insights

    View All

    KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

    Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

    3/4/26 8:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care